LUNG — Pulmonx Corp

Pulmonx Corp (LUNG) is a medical devices company listed on NASDAQ. It is led by Steven S. Williamson, based in 700 Chesapeake Drive, Redwood City, CA, United States, 94063, with about 291 employees. Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Latest reported LUNG revenue for 2025-09-30 was $21.5M. Net income was -$14.0M. Revenue was down 9.9% from 2025-06-30 to 2025-09-30. LUNG currently screens at market cap $111.9M.

Use this LUNG page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LUNG quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LUNG SEC filings page. Lician reads the product cache first so this HTML stays unique to Pulmonx Corp even when a live quote feed is slow.